MVM Partners led the financing for the Galway, Ireland-based company. Sofinnova Partners also provided significant participation. Existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland. In connection with the funding, MVM Partner Kyle Dempsey and Sofinnova Partner Cedric Moreau joined the company’s board.
Neurent plans to use the funds to drive commercial expansion, broaden clinical evidence and advance its product and indication pipeline.
The company develops the Neuromark system for treating chronic rhinitis. Neuromark features a flexible shaft and atraumatic leaflets that conform to the patient anatomy. This enables physicians to reach challenging areas in the nasal cavity while maximizing treatment coverage. The system delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals. This addresses the key symptoms of chronic rhinitis, such as persistent nasal congestion and rhinorrhea (runny nose).
eurent designed the system to optimize the treatment of posterior nasal nerves. It provides real-time feedback, guides proper electrode placement and confirms successful treatment delivery. The next-generation edition of the system picked up FDA clearance in June 2025.
“I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in medtech investing,” said CEO of Neurent Medical, Brian Shields. “This Series C financing will support our commercial expansion and help bring Neuromark to the patients and physicians who need it most. Our mission since inception has been to meaningfully improve patients’ lives while empowering ENT physicians with predictable, minimally invasive care. In addition to expanding patient access, this investment will also enable further evidence generation across broader populations and support the continued development of our exciting pipeline offerings.”
